# BME100 s2016:Group16 W1030AM L2

BME 100 Spring 2016 | Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
| ||||||

## Contents## OUR TEAM## LAB 2 WRITE-UP## Descriptive Statistics
## Results
## Analysis
Rat Test For the rats a t-test was used because there were only two groups in the study. P-Value:0.8674035 pg/mL The P-Value was greater than 0.05 causing there to be no significance between the two data sets.
Human Test For humans an Anova test was used since there were more than two groups in the study. P-Value:.008333333 Post-hoc Tests
## Summary/DiscussionBased off of the analysis of the data given, the Inflammotin protein levels in the elderly humans were significantly effected depending on the dosage of lipopolysaccharide (LPS). As the dosage increased from 0mg to 15mg of LPS, the protein levels decreased. This meant that there was less inflammation in the elderly humans. We used an unpaired analysis of variance test (ANOVA) and a bonferroni correction test (t-test) to determine that the data did have significance because there were several groups being compared. Based off of the analysis of the data given, the Inflammotin protein levels in the rats had no statistical significance. We used an unpaired t-test for this trial because there were only two groups being compared. We can not conclude anything from the data provided. These different results could have been for many reasons. One of the big factors is that there were not enough groups or subjects in the rat trial to have a significant difference in the dosages. Also, the drug could've had different responses in the rats than it did in the humans due to the difference in the digestion process, immune systems, and body mass. The lowest possible dose of lipopolysaccharide that would increase Inflammotin in the elderly is 5mg. However, if a higher Inflammotin level is desired, the dosage of lipopolysaccharide would need to be increased. |